Literature DB >> 21506148

Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.

Zang-Hee Cho1, Se-Hong Oh, Jong-Min Kim, Sung-Yeon Park, Dae-Hyuk Kwon, Hye-Jin Jeong, Young-Bo Kim, Je-Geun Chi, Chan-Woong Park, John Huston, Kendall H Lee, Beom S Jeon.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder resulting from progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta. Therefore, imaging of the SN has been regarded to hold greatest potential for use in the diagnosis of PD. At the 7.0T magnetic resonance imaging (MRI), it is now possible to delineate clearly the shapes and boundaries of the SN. We scanned eight early and two advanced PD patients, along with nine age-matched control subjects, using a 7.0T MRI in an attempt to directly visualize the SN and quantify the differences in shape and boundaries of SN between PD subjects in comparison with the normal control subjects. In the normal controls, the boundaries between the SN and crus cerebri appear smooth, and clean "arch" shapes that stretch ventrally from posterior to anterior. In contrast, these smooth and clean arch-like boundaries were lost in PD subjects. The measured correlation analyses show that, in PD patients, there is age-dependent correlation and substantially stronger UPDRS motor score-dependent correlation. These results suggest that, by using 7.0T MRI, it appears possible to use these visible and distinctive changes in morphology as a diagnostic marker of PD.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21506148     DOI: 10.1002/mds.23465

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  29 in total

Review 1.  The future of ultra-high field MRI and fMRI for study of the human brain.

Authors:  Jeff H Duyn
Journal:  Neuroimage       Date:  2011-10-28       Impact factor: 6.556

Review 2.  Contributions to magnetic susceptibility of brain tissue.

Authors:  Jeff H Duyn; John Schenck
Journal:  NMR Biomed       Date:  2016-05-30       Impact factor: 4.044

3.  Genetics of Parkinson disease.

Authors:  E Ben-David; R Tu
Journal:  AJNR Am J Neuroradiol       Date:  2014-09-04       Impact factor: 3.825

Review 4.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

5.  A multicontrast approach for comprehensive imaging of substantia nigra.

Authors:  Jason Langley; Daniel E Huddleston; Xiangchuan Chen; Jan Sedlacik; Nishant Zachariah; Xiaoping Hu
Journal:  Neuroimage       Date:  2015-02-28       Impact factor: 6.556

Review 6.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

Review 7.  [Ultrahigh field MRI in context of neurological diseases].

Authors:  J Kuchling; T Sinnecker; I Bozin; J Dörr; V I Madai; J Sobesky; T Niendorf; F Paul; J Wuerfel
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 8.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

Review 9.  A review of the use of magnetic resonance imaging in Parkinson's disease.

Authors:  Nadya Pyatigorskaya; Cécile Gallea; Daniel Garcia-Lorenzo; Marie Vidailhet; Stéphane Lehericy
Journal:  Ther Adv Neurol Disord       Date:  2014-07       Impact factor: 6.570

Review 10.  In-vivo human brain molecular imaging with a brain-dedicated PET/MRI system.

Authors:  Zang Hee Cho; Young Don Son; Eun Jung Choi; Hang Keun Kim; Jeong Hee Kim; Sang Yoon Lee; Seiji Ogawa; Young Bo Kim
Journal:  MAGMA       Date:  2012-08-03       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.